SpringWorks Therapeutics, Inc. (SWTX) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Stamford, CT, United States. Le PDG actuel est Saqib Islam.
SWTX a date d'introduction en bourse 2019-09-13, 368 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $3.54B.
SpringWorks Therapeutics, Inc. is a biopharmaceutical company founded in 2017 that acquires, develops, and commercializes medicines targeting underserved patient populations with rare diseases and cancer. The company's lead product candidate, nirogacestat, is an oral gamma secretase inhibitor currently in Phase III clinical trials for desmoid tumors, while its clinical pipeline includes mirdametinib, a MEK inhibitor being evaluated for neurofibromatosis type 1-associated plexiform neurofibromas and solid tumors, as well as BGB-3245 for BRAF-mutant cancers. SpringWorks has established strategic collaborations and licensing agreements with major pharmaceutical companies including BeiGene, GlaxoSmithKline, Pfizer, and others to advance combination therapies and expand its therapeutic capabilities. Headquartered in Stamford, Connecticut, the company focuses on developing innovative small molecule inhibitors across multiple oncology and rare disease indications.
